ArticleMalignant Meningiomas Management and OutcomeViswanathan, Ashwin MD; DeMonte, Franco MD Author Information Dr. Viswanathan is Chief Resident, Department of Neurosurgery, Baylor College of Medicine, Houston, TX; and Dr. DeMonte is Professor, Mary Beth Pawelek Chair in Neurosurgery, Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 442, Houston, TX 77030; E-mail: [email protected]. The authors have disclosed that they have no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. The authors also have disclosed that the use of interferon alpha, imatinib, thalidomide, erlotinib, bevacizumab, and sunitinib for treatment of malignant meningioma as discussed in this article has not been approved by the U.S. Food and Drug Administration. All staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Category: Tumor Contemporary Neurosurgery: December 15, 2008 - Volume 30 - Issue 25 - p 1-7 doi: 10.1097/01.CNE.0000341718.73002.44 Buy CME Test Metrics © 2008 Lippincott Williams & Wilkins, Inc.